Sprycel

(Dasatinib)

ApprovedProtein / enzyme

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Dasatinib is used to treat certain types of blood cancers, particularly chronic myeloid leukemia and acute lymphoblastic leukemia, by stopping cancer cells from growing and multiplying.[2] Sprycel is currently approved and in use across 64 indications[4].[1]

Sprycel is one of 1312 small molecule programs targeting Glioma. It is currently in Approved.

Indications

321

Total Trials

Active Trials

1,311

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Childhood CancerActive, not recruiting

Polycythemia VeraActive, not recruiting

Bone MetastasisActive, not recruiting

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

MacroglobulinemiaActive, not recruiting

T-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Lung CancerActive, not recruiting

Bladder Transitional Cell CarcinomaActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseActive, not recruiting

GliomaPhase 2

Active, not recruiting

Childhood CancerPhase 2

Active, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Bone MetastasisPhase 1/Phase 2

Active, not recruiting

Adult Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

MacroglobulinemiaPhase 1

Active, not recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Bladder Transitional Cell CarcinomaPreclinical

Active, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 1/Phase 2

Active, not recruiting

Showing 10 of 64 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

14 2

Trodelvy

Gilead

Preclinical

37 3

Prolia

Amgen

Preclinical

14 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Tricor

JJagotec

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

MPR

NCT07144293

Post-ApprovalRecruiting

Children

NCT03844360

Q1 2027

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT00792948

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT02143414

Phase 2Recruiting

Trial

NCT03297606

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05192889

Clinical

Trials by Indication[1]

Myeloid Leukemia26 trials

Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01660906·39 enrolled

Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

Completed·NNorwegian University of Science and Technology·Phase 2·NCT01725204·40 enrolled

Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00324077

Show 23 more trials

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07269470·40 enrolled

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib

Completed·KKanto CML Study Group·Phase 2·NCT01342679·21 enrolled

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00103844·150 enrolled

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02011945·35 enrolled

Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01218477·33 enrolled

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Completed·KKanto CML Study Group·Phase 2·NCT00866736·65 enrolled

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

Completed·NNorwegian University of Science and Technology·Phase 2·NCT00852566·46 enrolled

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00320190·52 enrolled

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101647·197 enrolled

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Completed·HHikma Pharmaceuticals LLC·Phase 2·NCT03625388·56 enrolled

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02546791·101 enrolled

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Unknown status·SShimousa Hematology Study Group·Phase 2·NCT01627132·50 enrolled

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Active, not recruiting·SSWOG Cancer Research Network·Phase 2·NCT03654768·81 enrolled

A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00482703·23 enrolled

Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02389972·128 enrolled

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101816·124 enrolled

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01850004·84 enrolled

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Unknown status·PPETHEMA Foundation·Phase 2·NCT01802450·18 enrolled

Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

Unknown status·AAmsterdam UMC, location VUmc·Phase 2·NCT03573596·134 enrolled

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT01751425·8 enrolled

Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Recruiting·MMedical College of Wisconsin·Phase 2·NCT04838041·51 enrolled

A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 4·NCT04925141·62 enrolled

Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00101660·387 enrolled

Acute Lymphoblastic Leukemia23 trials

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruiting·—·Phase 3·NCT03020030·560 enrolled

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02143414·53 enrolled

Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00940524·7 enrolled

Show 20 more trials

Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Unknown status·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT03318770·60 enrolled

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Recruiting·HHyoung Jin Kang·Phase 2·NCT06257394·74 enrolled

Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients

Unknown status·TTongji Hospital·Phase 4·NCT02690922·40 enrolled

Ma-Spore ALL 2020 Study

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT06336395·500 enrolled

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00390793·107 enrolled

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00792948·97 enrolled

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00103701

Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02420717·11 enrolled

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Completed·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT02523976·30 enrolled

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Recruiting·UUniversity of Chicago·Phase 2·NCT04747912·25 enrolled

Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00036738·28 enrolled

Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00982488·238 enrolled

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04329325·17 enrolled

Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

Completed·GGrupo Espanol de trasplantes hematopoyeticos y terapia celular·Phase 2·NCT01310010·30 enrolled

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00316953·48 enrolled

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT00720109·63 enrolled

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06533748·128 enrolled

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia

Completed·VVersailles Hospital·Phase 2·NCT02888990·71 enrolled

Chronic Myelogenous Leukemia10 trials

Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT05638763·15 enrolled

Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00123474·724 enrolled

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00777036·133 enrolled

Show 7 more trials

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT00064233·42 enrolled

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01426334·4 enrolled

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00298987·400 enrolled

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01498445·32 enrolled

Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00978731·46 enrolled

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02689440·155 enrolled

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00254423·150 enrolled

Breast Cancer7 trials

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Terminated·UUniversity of Wisconsin, Madison·Phase 2·NCT02720185·5 enrolled

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00903006·11 enrolled

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00696072·120 enrolled

Show 4 more trials

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Completed·AAccelerated Community Oncology Research Network·Phase 1/2·NCT00924352·56 enrolled

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00371254·55 enrolled

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00754325·100 enrolled

Phase II Dasatinib Study in Advanced Breast Cancer

Completed·—·Phase 2·NCT00546104·31 enrolled

Non-Small Cell Lung Cancer6 trials

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01999985·25 enrolled

Phase II Study Evaluating The Safety And Response To Neoadjuvant Dasatinib In Early Stage Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT00564876·2 enrolled

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02750514·295 enrolled

Show 3 more trials

Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00858403·7 enrolled

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Terminated·CChul Kim·Phase 1/2·NCT02954523·10 enrolled

Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00826449·53 enrolled

92 more indications

Treatment6 trials

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT04439305

Treatment of Adult Ph+ LAL With BMS-354825

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 2·NCT00391989·53 enrolled

A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)

Unknown status·NNational Research Center for Hematology, Russia·Phase 2·NCT04578847·100 enrolled

Show 3 more trials

Treatment-free Remission Accomplished With Dasatinib in Patients With CML

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT02268370·131 enrolled

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02297139·17 enrolled

Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01260688·22 enrolled

Chronic Lymphocytic Leukemia5 trials

A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

Terminated·UUniversity of California, San Diego·Phase 1/2·NCT00949988·3 enrolled

A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia

Withdrawn·SScripps Health·Phase 1/2·NCT00829647

Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT01441882·19 enrolled

Show 2 more trials

Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00563290·7 enrolled

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00872976

Prostate Cancer5 trials

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Terminated·—·Phase 2·NCT00918385·57 enrolled

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Completed·UUniversity of California, Irvine·Phase 2·NCT00570700·38 enrolled

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00385580·94 enrolled

Show 2 more trials

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

Terminated·NNoah Hahn, M.D.·Phase 2·NCT00860158·1 enrolled

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00744497·1,930 enrolled

Acute Myeloid Leukemia4 trials

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Withdrawn·EEmory University·Phase 1·NCT02680951

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT03173612·132 enrolled

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Withdrawn·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT03560908

Show 1 more trial

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01238211·61 enrolled

Alzheimer's Disease3 trials

Senolytic Therapy to Modulate Progression of Alzheimer's Disease

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT04063124·5 enrolled

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT04685590·48 enrolled

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

Completed·LLewis Lipsitz·Phase 1/2·NCT05422885·15 enrolled

Multiple Myeloma3 trials

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·MMayo Clinic·Phase 2·NCT06940297·44 enrolled

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01609816·8 enrolled

A Phase II Study of Dasatinib in the Treatment of Relapsed or Plateau Phase Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 2·NCT00429949·21 enrolled

Glioblastoma Multiforme3 trials

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00869401·217 enrolled

Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00892177·144 enrolled

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00423735·64 enrolled

Metastatic Colorectal Cancer3 trials

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·OOslo University Hospital·Phase 2·NCT05725200·40 enrolled

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00501410·86 enrolled

Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00504153·19 enrolled

Chemotherapy2 trials

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05026229·60 enrolled

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Completed·UUniversity of Ulm·Phase 3·NCT02013648·204 enrolled

ART2 trials

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01392703·141 enrolled

KISS Study: Kinase Inhibition With Sprycel Start up

Unknown status·UUniversity of Auckland, New Zealand·Phase 2·NCT03193281·91 enrolled

Tics2 trials

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00655746·14 enrolled

Senolytics for Secondary Progressive MS

Not yet recruiting·OOhio State University·Phase 1·NCT07270120·30 enrolled

Trial2 trials

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Lung Cancer2 trials

Dasatinib in Treating Patients With Advanced Lung Cancer That Is No Longer Responding to Erlotinib or Gefitinib

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00570401·22 enrolled

Dasatinib in Advanced Squamous Cell Lung Cancer

Terminated·—·Phase 2·NCT01491633·5 enrolled

Pancreatic Cancer2 trials

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00474812·51 enrolled

Dasatinib in Treating Patients With Stage IV Pancreatic Cancer

Terminated·—·Phase 2·NCT00544908·7 enrolled

Gastrointestinal Stromal Tumor2 trials

Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01643278·29 enrolled

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Completed·SSwiss Cancer Institute·Phase 2·NCT00568750·47 enrolled

Glioblastoma2 trials

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00948389·28 enrolled

Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00895960·16 enrolled

CML2 trials

Rollover Study of BMS-354825 in Patients With CML and Ph+ALL

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01030718·54 enrolled

Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00337454·48 enrolled

Efficacy and Safety1 trial

The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients

Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT04933526·118 enrolled

Glioma1 trial

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03352427·3 enrolled

Breast Carcinoma1 trial

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00820170·55 enrolled

Randomized1 trial

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Available·PPusan National University Hospital··NCT00854841

Dexamethasone1 trial

Dasatinib in Combination With Revlimid (and Dexamethasone)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00560391·35 enrolled

COVID-191 trial

Dasatinib for the Treatment of Moderate and Severe COVID-19

Withdrawn·UUniversity of Southern California·Phase 2·NCT04830735

Fasting Conditions1 trial

Evaluating the Effects of Omeprazole on the Pharmacokinetics of XS004 (Dasatinib) Tablets in Healthy Adult Subjects Under Fasting Conditions

Completed·XXspray Pharma AB·Phase 1·NCT05433896·17 enrolled

Childhood Cancer1 trial

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT04733534·110 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

Completed·—·Phase 1/2·NCT05506488·30 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial

Completed·WWake Forest University Health Sciences·Phase 1·NCT02874989·26 enrolled

Aging1 trial

Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging

Unknown status·TTruDiagnostic·Phase 2·NCT04946383·25 enrolled

Carboplatin1 trial

PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer

Completed·AAA Secord·Phase 1·NCT00672295·11 enrolled

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00162214·60 enrolled

Cisplatin1 trial

A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00882583·22 enrolled

Mastocytosis1 trial

Evaluation of Response of Dasatinib to Treat Mastocytosis

Unknown status·FFederico II University·Phase 2·NCT00979160·30 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00918463·2 enrolled

Advanced Cancer1 trial

Dasatinib and Crizotinib in Advanced Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01744652·62 enrolled

Peritoneal Cancer1 trial

Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02059265·35 enrolled

Endometrial Cancer1 trial

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

Completed·UUniversity of Virginia·Phase 1·NCT01482728·12 enrolled

Clinical Trial1 trial

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Withdrawn·BBio-Path Holdings, Inc.·Phase 1/2·NCT02923986

Diagnosis1 trial

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564470·120 enrolled

Refractory Solid Tumor1 trial

Phase I (PH I) Mad Refractory Solid Tumor Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00099606·60 enrolled

First-line Treatment1 trial

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT04155411·65 enrolled

Malignant Mesothelioma1 trial

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00509041·46 enrolled

Patients With Solid Tumors1 trial

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00339144·16 enrolled

Bone Metastasis1 trial

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00566618·31 enrolled

Refractory Metastatic1 trial

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

Unknown status·PPeking University Cancer Hospital & Institute·N/A·NCT02776878·57 enrolled

Maintenance Therapy1 trial

A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·N/A·NCT05024357·80 enrolled

Melanoma1 trial

Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01092728·19 enrolled

SMA1 trial

Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction

Recruiting·SSt Vincent's Hospital, Sydney·Phase 2·NCT04925648·22 enrolled

Advanced NSCLC1 trial

Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC

Terminated·—·Phase 2·NCT00787267·37 enrolled

Primary Peritoneal Carcinoma1 trial

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Completed·GGynecologic Oncology Group·Phase 2·NCT00671788·35 enrolled

Pulmonary Fibrosis1 trial

Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00764309·47 enrolled

Liver1 trial

A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT00382668·40 enrolled

Pancreatic Adenocarcinoma1 trial

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

Completed·UUniversity of Florida·Phase 2·NCT01652976·44 enrolled

Phase 21 trial

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01357655·70 enrolled

Children1 trial

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

Recruiting·WWei Zhao·Phase 4·NCT03844360·1,500 enrolled

Leukaemia1 trial

Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

Completed·NNewcastle University·Phase 3·NCT01460693·814 enrolled

MPR1 trial

Improving Physical Ability and Cellular Senescence Elimination in HIV

Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07144293·82 enrolled

Metastatic Melanoma1 trial

Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma

Completed·—·Phase 2·NCT01876212·15 enrolled

Tyrosine Kinase Inhibitor1 trial

Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02733445·2,650 enrolled

Leukemia1 trial

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

Completed·UUniversity Hospital, Angers·Phase 2·NCT02113319·27 enrolled

Triple-Negative Breast Cancer1 trial

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Terminated·BBaylor Breast Care Center·Phase 2·NCT00817531·22 enrolled

Pediatric1 trial

Newly-diagnosed Pediatric T-cell ALL Protocol

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2/3·NCT06855810·610 enrolled

Recurrent or Metastatic1 trial

Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00859937·55 enrolled

Advanced Malignancies1 trial

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01015222·122 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Terminated·UUniversity of California, San Diego·Phase 2·NCT02043587·31 enrolled

Antiretroviral Treatment1 trial

Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

Completed·FFundació Institut Germans Trias i Pujol·Phase 2·NCT05780073·60 enrolled

Advanced Cancers1 trial

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01514864·19 enrolled

Stem Cell Transplant1 trial

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

Not yet recruiting·TThe University of Hong Kong·Phase 2·NCT07493408·45 enrolled

Mucosal Melanoma1 trial

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00700882·81 enrolled

Philadelphia Chromosome Positive1 trial

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00349518

Hematologic Malignancies1 trial

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 1·NCT01643603·5 enrolled

Tyrosine Kinase Inhibitors1 trial

Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients

Completed·UUNC Lineberger Comprehensive Cancer Center··NCT03885830·45 enrolled

Pediatric Patients1 trial

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Unknown status·SSeattle Children's Hospital·N/A·NCT02015728·20 enrolled

Molecular Targeted Therapy1 trial

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Completed·UUniversity of Regensburg·Phase 2·NCT02596828·4 enrolled

Liver Cancer1 trial

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00459108·25 enrolled

HER2 Positive1 trial

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Completed·SSpanish Breast Cancer Research Group·Phase 1/2·NCT01306942·37 enrolled

Malignant Solid Tumors1 trial

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Terminated·—·Phase 1/2·NCT00788125·7 enrolled

Relapsed or Refractory1 trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Gastric1 trial

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Completed·UUniversity of California, San Francisco·Phase 1·NCT01398046·10 enrolled

Osteoporosis1 trial

Senolytics to Improve Osteoporosis Therapy

Active, not recruiting·OOdense University Hospital·Phase 2·NCT06018467·120 enrolled

Myeloproliferative Disorder1 trial

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00255346·68 enrolled

Myelodysplastic Syndrome1 trial

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

Completed·UUniversity of Pittsburgh·Phase 1·NCT00892190·9 enrolled

Advanced Sarcoma1 trial

Trial of Dasatinib in Advanced Sarcomas

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00464620·366 enrolled

Refractory1 trial

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Terminated·MMassachusetts General Hospital·Phase 2·NCT01173679·10 enrolled

Malignant Pleural Mesothelioma1 trial

Dasatinib in Resectable Malignant Pleural Mesothelioma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00652574·56 enrolled

T-cell acute lymphoblastic leukemia1 trial

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06390319·100 enrolled

Cognitive Function1 trial

Fortifying Healthy Behaviors, Optimizing Medical Therapies and Enhancing Cognitive Function in Older Adults-pilot Study

Recruiting·WWashington University School of Medicine·Phase 2·NCT07000734·20 enrolled

Advanced Solid Tumors1 trial

Gemcitabine and Dasatinib in Advanced Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00429234·54 enrolled

Androgen Deprivation Therapy1 trial

Study of Dasatinib, Androgen Deprivation Therapy and Radiation

Withdrawn·—·Phase 1·NCT01826838

Advanced Hematologic Malignancies1 trial

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

Active, not recruiting·KKumquat Biosciences Inc.·Phase 1·NCT06645886·13 enrolled

Unspecified4 trials

Study of Erlotinib in Combination With Dasatinib

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00895128·65 enrolled

A Phase I/Expansion Study of Dasatinib

Terminated·—·Phase 1·NCT00598091·30 enrolled

Explore the Synergy of Combination TKI Therapy

Withdrawn·UUniversity of Florida·Phase 1·NCT02129166

Show 1 more trial

Bioequivalence Studies of Dasatinib 100 Mg

Not yet recruiting·CCentro de Atencion e Investigacion Medica·Phase 4·NCT05944783·46 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 28, 2006

SPRYCEL

NDA NDA021986

Dec 5, 2023

PHYRAGO

NDA NDA216099

Sources

References

[1]
ClinicalTrials.gov — 321 trial records for Dasatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Sprycel drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Dasatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Dasatinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216099). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Sprycel. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Bcr/abl Fusion Protein Inhibitor[3]
Modality: Protein / enzyme[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

Sep 28, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7491725Mar 28, 2026

7491725*PEDSep 28, 2026

11202778Jan 22, 2041

12433891Jan 22, 2041

12544376Jan 22, 2041

3 more patents

11298356Jan 22, 2041

12465606Jan 22, 2041

11324745Jan 22, 2041

Sprycel

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Myeloid Leukemia26 trials

Acute Lymphoblastic Leukemia23 trials

Chronic Myelogenous Leukemia10 trials

Breast Cancer7 trials

Non-Small Cell Lung Cancer6 trials

Treatment6 trials

Chronic Lymphocytic Leukemia5 trials

Prostate Cancer5 trials

Acute Myeloid Leukemia4 trials

Alzheimer's Disease3 trials

Multiple Myeloma3 trials

Glioblastoma Multiforme3 trials

Metastatic Colorectal Cancer3 trials

Chemotherapy2 trials

ART2 trials

Tics2 trials

Trial2 trials

Lung Cancer2 trials

Pancreatic Cancer2 trials

Gastrointestinal Stromal Tumor2 trials

Glioblastoma2 trials

CML2 trials

Efficacy and Safety1 trial

Glioma1 trial

Breast Carcinoma1 trial

Randomized1 trial

Dexamethasone1 trial

COVID-191 trial

Fasting Conditions1 trial

Childhood Cancer1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Idiopathic Pulmonary Fibrosis1 trial

Aging1 trial

Carboplatin1 trial

Dacarbazine1 trial

CAR T Cell Therapy1 trial

Patients With Advanced Solid Tumors1 trial

Cisplatin1 trial

Mastocytosis1 trial

Diffuse Large B-Cell Lymphoma1 trial

Advanced Cancer1 trial

Peritoneal Cancer1 trial

Endometrial Cancer1 trial

Clinical Trial1 trial

Diagnosis1 trial

Refractory Solid Tumor1 trial

First-line Treatment1 trial

Malignant Mesothelioma1 trial

Patients With Solid Tumors1 trial

Bone Metastasis1 trial

Refractory Metastatic1 trial

Maintenance Therapy1 trial

Melanoma1 trial

SMA1 trial

Advanced NSCLC1 trial

Primary Peritoneal Carcinoma1 trial

Pulmonary Fibrosis1 trial

Liver1 trial

Pancreatic Adenocarcinoma1 trial

Phase 21 trial

Children1 trial

Leukaemia1 trial

MPR1 trial

Metastatic Melanoma1 trial

Tyrosine Kinase Inhibitor1 trial

Leukemia1 trial

Triple-Negative Breast Cancer1 trial

Pediatric1 trial

Recurrent or Metastatic1 trial

Advanced Malignancies1 trial

Adult Acute Lymphoblastic Leukemia1 trial

Antiretroviral Treatment1 trial

Advanced Cancers1 trial